Aflibercept vs Aflibercept (Eyluxvi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Aflibercept (Eyluxvi)

Marketed by Biolitec Pharma and partners

fusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Aflibercept (Eyluxvi): no structured comparison results are available for Age-Related Macular Degeneration.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
NEI VFQ-25 Total 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4
absolute change · score
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 5 more results
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 6.3 Ranibizumab score @ 52wk2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.9 vs 6.3 Ranibizumab score @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.1 vs 6.3 Ranibizumab score @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14 vs 3.9 PDT Letters correctly read @ 28wk
NCT01482910 · Phase 3 · registry result, not featured evidence
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 8.1 ETDRS Letters @ 52wk
absolute change · ETDRS Letters
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 ETDRS Letters @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
CST Change Microns -248.8 um @ 52wk
absolute change · um
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
-164.8 um @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
Complete Polyp Regression 53.8% (n=39) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 1 more result
38.5% (n=13) @ 52wk*
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
BCVA Letters 0.3 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.33 score @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
CST Change Microns 0.08 ratio @ 24wk
ratio to baseline · ratio
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.07 ratio @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence

+ 63 further endpoints in the CSV export.

Available safety results

Aflibercept

Dropout rate
3.6%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
4.9%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%
NCT03022292 · Phase 4 · registry result, not featured evidence
6.1%
NCT02689518 · Phase 4 · registry result, not featured evidence
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
100%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
8.7%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
12.7%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
6.3%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.2%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
6.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
23.6%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
Discontinued due to AEs
1%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
20%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
2.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
3.2%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—
NCT01950741 · Phase 4 · registry result, not featured evidence
—2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
2.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
3.2%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
Serious AEs
23%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
26.7%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
15.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
17.2%Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
2.1%
NCT01950741 · Phase 4 · registry result, not featured evidence
20%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
2.3%Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
5.7%Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
4.2%PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
45.9%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
Most frequent reported AEs
2.0mg Q4
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 39 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
drop in visual acuity 7.7%
punctate epithelial erosion 7.7%
raised blood pressure 7.7%
NCT03117634 · Phase 4 · registry result, not featured evidence
drop in vision due to cataract 5.1%
drop in visual acuity 5.1%
peri-orbital oedema (extra-ocular) 2.6%
NCT03117634 · Phase 4 · registry result, not featured evidence
myelodysplastic syndrome 3.8%
pneumonia 3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
hypertension 13.3%
depression 6.7%
ocular hypertension 6.7%
NCT02120950 · Phase 4 · registry result, not featured evidence
viral upper respiratory tract infection 11.2%
hypertension 8.1%
dry eye 6.8%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
viral upper respiratory tract infection 15.9%
conjunctival haemorrhage 6.4%
vitreous floaters 5.7%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
conjunctival hemorrhage 8.5%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.0 mg
cataract progression 6.7%
geographic atrophy progression 6.7%
NCT01543568 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
conjunctival haemorrhage 6%
macular fibrosis 2.8%
retinal pigment epitheliopathy 2.8%
NCT01482910 · Phase 3 · registry result, not featured evidence
macular fibrosis 11.8%
visual acuity reduced 7%
conjunctival haemorrhage 6.1%
NCT01482910 · Phase 3 · registry result, not featured evidence
visual acuity reduced 7%
conjunctival haemorrhage 5.6%
intraocular pressure increased 1.4%
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
2mg
fall 18.5%
hypertension 16.6%
nasopharyngitis 16.6%
NCT00527423 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Aflibercept (Eyluxvi)'s landscape